Digital Events | Kisaco Research
Filter by:
 
Women's Health Innovation Summit 2020
14-22 Sep 2020
VIRTUAL SUMMIT | EDT Timezone
Women’s health today is under-served from an innovation and clinical science standpoints with outdated practices and lack of much-needed attention from key players (incl. investors and insurers). It is imperative to develop the eco-system, shift mindsets and embrace the holistic women-centred approach.The Women’s Health Innovation Summit (WHI) is THE forum for pharmaceutical and medical devices companies, start-ups and investors, doctors, researchers and HCPs, employers and insurers to drive innovation at the convergence of healthcare and technology.We tackle the female prevalent verticals (e.g. contraception, pregnancy, breast cancer, and fertility), as well as other verticals including cardiovascular diseases, inconsistency, diabetes, mental health, sexual health amongst others.This event is for strengthening and advancing research, investments and partnerships to ultimately improve the access and quality of healthcare for women worldwide.To make the difference and to move your business forward, join us!
 
European Protein Degradation Congress 2020
28-30 Sep 2020
Virtual Congress | CEST Timezone
With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs, eyes are focused on how much further protein degradation-based therapeutics will continue to growwithin the pharmaceutical industry.Following huge success in May 2019, the 2nd European Protein Degradation Congress, returns to Switzerland 28th-30th September 2020, where you can hear the most up to date and relevant information for the broad range of topics in the field of targetedprotein degradation.New areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown.Leading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway, providing a clearer picture on what makes a good, or not good, target for degradation.
 
Targeting the Undrugged 2020
20-23 Oct 2020
VIRTUAL CONGRESS | EDT Timezone
With up to 85% of the human proteome currently undrugged, a new wave of technology is arriving, there is a scientific environment that is primed for innovation in targeting undrugged targets.Development of these technologies has seen millions of dollars of investment and with different approaches quickly thrust into the limelight following recent success stories, lessons are becoming increasingly valuable across research.Introducing Targeting the Undrugged, a virtual summit taking place across Oct 20th - 23rd. Tune in to join leading global pharmaceutical companies, biotechs and academics to explore the latest research and case studies, take away actionable insights including:Clinical study data on small molecule modalities targeting oncogenic transcription factorsNovel strategies for targeting RNA through computational studiesLeading insights on target identification for protein misfolding product developmentDevelop analogous small molecule approaches to PROTACS used in protein degradation and apply cross specialityTranslate the latest transcription factor research into druggable approaches for safe and efficacious therapeuticsMove from disease treatment to prevention through RNA targetingPromoting Strategies for Cross Speciality learnings for the undrugged spaceValidate targets and their role in protein conformational disease and accelerate their translation into the clinic
 
26-27 Jan 2021
London, United Kingdom
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.Whilst bringing together the key decision-makers for CAR-T therapies, this year’s event will have an added focus on the groundbreaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.The event will be comprised of research on CAR-T and alternative cell therapies, plus increasing the affordability of treatment. The other tracks will delve into best practices in the commercialisation, regulation, and manufacturing of immuno-oncological cell therapies.Each day of the summit will break down the key challenges in major topics within R&D, manufacturing, and commercialisation.
Filter by:
 
Protein Engineering Congress USA 2020
27-29 Jul 2020
VIRTUAL CONGRESS | PDT Timezone
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimize performance greater than ever. The virtual Protein Engineering Congress is dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.With industry approaching the design, build, and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering.The breadth of topics discussed at this meeting will focus in on directed evolution, computational protein design, synthetic biology and white biotechnology, and applications of enzyme and protein engineering and industrial biocatalysis in the biopharmaceutical, flavor & fragrance, cosmetics, and food industries.Attend and you'll be able to:Network with key opinion leaders and acquire new customersForm collaborations with companies who are engineering proteins and enzymesMeet with new technology partners to enhance internal R&DUnderstand the new applications of engineered enzymes and learn how to scale-up to large industrial manufacture
 
OCTS 2020
7-9 Jul 2020
VIRTUAL SUMMIT | EDT Timezone
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
 
Transcription Factor Drug Development
6-9 Jul 2020
VIRTUAL SUMMIT | CEST Timezone
With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting transcription factors that were previously thought to be “undruggable”, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within cancer and other disease settings. With multiple strategies having entered the clinic from PPI inhibitors, modulators of TF expression, and the first PROTAC-based degraders, it could only be a matter of time before the first therapy enters the market.The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world! We will bring together leading industry players within large pharma and biotech, along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.Develop further insight into targeting MYC, STAT, and other transcription factors with a role in disease. 
m